Xerostomia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (OTC, Prescription), By Product, By Region, And Segment Forecasts, 2023 - 2032
- Published Date:Oct-2023
- Pages: 115
- Format: PDF
- Report ID: PM1339
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global xerostomia therapeutics market was valued at USD 2.08 billion in 2022 and is expected to grow at a CAGR of 3.5% during the forecast period.
One significant factor is the increasing adoption of chemotherapy and radiotherapy in cancer treatment. Chemotherapy and radiotherapy are essential components of cancer therapy, employed to target and eradicate cancer cells. However, these treatments can have side effects, one of which is damage to the salivary glands. In the context of cancer treatment, the salivary glands are often exposed to radiation or affected by chemotherapy drugs.
To Understand More About this Research: Request a Free Sample Report
This exposure can disrupt the normal functioning of these glands, leading to a reduction in saliva production and resulting in dry mouth or xerostomia. As these cancer treatment modalities become more prevalent in medical practice, the incidence of xerostomia as a side effect is expected to increase, driving the demand for treatments to alleviate this condition.
Additionally, the growing use of prescribed medications is another factor contributing to the market's growth. Xerostomia can also be a side effect of various medications, particularly those used to manage chronic health conditions. As healthcare providers prescribe these medications to a larger patient population, the occurrence of medication-induced xerostomia is expected to rise. Various products designed to alleviate dry mouth symptoms include sugar-free gum, lozenges, toothpaste, oral-adhering discs, patches, melts, and oral rinses. These products come with reasonable reimbursement policies and are typically priced in a range from USD 10 to USD 90, making them accessible to a wide range of patients.
Xerostomia is a medical term that refers to a condition characterized by oral dryness, primarily caused by a reduction in the production of saliva in the mouth. This condition can manifest as a feeling of dryness in the mouth, a sensation of oral burning, difficulty in swallowing, and a decrease or loss of the sense of taste. It is worth noting that xerostomia can be a challenging and uncomfortable condition.
Industry Dynamics
Growth Drivers
Increased prevalence of oral health conditions.
The Xerostomia Therapeutics Market is experiencing a surge in demand due to the increased prevalence of oral health conditions. Xerostomia, commonly known as dry mouth, is a common side effect of various medical treatments and medications, contributing to its widespread occurrence. The rise in aging populations and the growing use of medications that induce xerostomia have heightened the need for effective therapeutics.
As the incidence of oral health issues continues to grow, including conditions like tooth decay and gum disease, the demand for xerostomia treatments has intensified. Patients experiencing dry mouth symptoms seek relief not only for comfort but also to prevent potential oral health complications.
This trend has prompted research and development efforts to enhance existing therapies and develop innovative solutions, driving advancements in the Xerostomia Therapeutics Market. As a result, healthcare providers, pharmaceutical companies, and patients are increasingly focusing on the management and treatment of xerostomia, creating opportunities for growth in the market.
Report Segmentation
The market is primarily segmented based on type, product, and region.
|
By Type |
By Product |
By Region |
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Type Analysis
The OTC segment accounted for the largest market share in 2022
The OTC segment accounted for the largest market share. This dominance can be attributed to the extensive variety and widespread availability of OTC products, their proven safety and efficacy, the presence of limited branded drugs, and the affordability of these products. OTC products serve as the frontline treatment for xerostomia, offering an accessible and convenient option for individuals experiencing dry mouth symptoms. Most cases of xerostomia can be effectively managed with OTC products, typically without complications. In instances where xerostomia is particularly severe, prescription medications may be necessary for treatment.
By Product Analysis
The salivary stimulants segment held a significant market share in 2022
The salivary stimulants segment held the majority market share in terms of revenue. Salivary stimulants refer to substances designed to enhance the production of saliva. They can be further categorized into two groups: pharmacological, which acts on the nervous system, and non-pharmacological, which influences taste buds or chewing muscles. These salivary stimulants are available in many forms, including mints, chewing gums, sprays, & lozenges.
For instance, in September 2021, ICPA Health. Introduced "Wet Mouth," a saliva substitute based on sodium carboxymethyl cellulose. This product was specifically designed to address xerostomia and offers relief by reducing surface abrasion in the mouth. Salivary stimulants play a crucial role in providing relief to individuals dealing with dry mouth symptoms and are available in convenient and user-friendly forms.
The dentifrices segment will grow at a robust pace. Dentifrices are specialized oral care products, including agents, powders, or pastes, designed to combat dry mouth by eliminating irritants responsible for this condition. For instance, GC America’s MI Paste & MI Paste Plus. These products can be applied to the teeth and serve a dual purpose: stimulating saliva production and restoring crucial components of saliva such as calcium and phosphate. By doing so, they contribute to alleviating dry mouth symptoms and promoting oral health. The dentifrices segment plays a significant role in offering effective solutions for individuals seeking relief from xerostomia.
Regional Insights
North America region dominated the global market in 2022
North America emerged as the largest region. There has been a notable increase in the prevalence of xerostomia, a condition characterized by dry mouth, in the region. Additionally, there is a rising incidence of other dry mouth-associated diseases, such as Sjogren's syndrome and rheumatoid arthritis, in the region. These medical conditions often lead to dry mouth as a symptom, further driving the demand for xerostomia treatments and products.
Moreover, there is an increase in awareness initiatives aimed at addressing the issue of dry mouth. One noteworthy example is the Sjogren's Foundation, which has taken proactive steps to raise awareness about Sjogren's syndrome, a condition that often leads to xerostomia. The foundation's "April is Sjogren's Awareness Month" campaign is one such initiative designed to educate the public and healthcare professionals about the syndrome and its associated symptoms, including dry mouth.
Asia Pacific region will grow rapidly. As economies grow and healthcare infrastructure improves, individuals have greater access to healthcare services, including treatment options for conditions like xerostomia. The increased investment in healthcare infrastructure and services has contributed to the growth of the xerostomia treatment market. Substantial rise in awareness-raising campaigns focused on oral health and related conditions, including xerostomia. These campaigns aim to educate the public about the causes, symptoms, and available treatments for dry mouth, leading to an increased demand for xerostomia treatment products.
Moreover, the prevalence of certain medical conditions, such as diabetes, cancer, and Parkinson's disease, has been on the rise in the region. Many of these conditions are associated with dry mouth as a symptom. For example, according to a study conducted by the National Institutes of Health (NIH), the incidence of Parkinson's disease saw significant increases in various Asian regions from 1990 to 2019. This growth in the prevalence of underlying medical conditions has resulted in a higher incidence of xerostomia cases, further propelling the demand for xerostomia treatments in the region.
Key Market Players & Competitive Insights
key players in the xerostomia treatment market are driven by a multi-faceted strategy that includes product portfolio development, strategic acquisitions, and distribution agreements. These approaches enable them to maintain a strong market position, cater to the needs of healthcare professionals and patients, and expand their geographical footprint in the competitive landscape.
Some of the major players operating in the global market include:
- Acacia Pharma
- Church & Dwight Co., Inc.
- Colgate-Palmolive Company
- GlaxoSmithKline plc
- Hikma Pharmaceuticals PLC
- Lupin Pharmaceuticals, Inc.
- OraCoat
- Parnell Pharmaceuticals, Inc.
- Pendopharm
- Pfizer, Inc.
- Sun Pharmaceuticals Industries Ltd.
Recent Developments
- In June 2023, MeiraGTx developed a treatment known as AAV-AQP1. This therapy has progressed to the Phase II clinical trial stage and is specifically designed for addressing xerostomia. Xerostomia can occur as a result of two primary causes: the use of ionizing radiation in head & neck cancer & the disease linked with Sjogren's syndrome.
Xerostomia Therapeutics Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 2.15 billion |
|
Revenue Forecast in 2032 |
USD 2.94 billion |
|
CAGR |
3.5% from 2023 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019 – 2021 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2023 to 2032 |
|
Segments Covered |
By Type, By Product, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global xerostomia therapeutics market size is expected to reach USD 2.94 billion by 2032.
Key players in the xerostomia therapeutics market are GlaxoSmithKline, Hikma Pharmaceuticals, Pendopharm, Sun Pharma
North America contribute notably towards the global xerostomia therapeutics market.
The global xerostomia therapeutics market is expected to grow at a CAGR of 3.5% during the forecast period.
The xerostomia therapeutics market report covering key segments are type, product, and region.
